 Verona Pharma PLC NASDAQ: VRNA has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation pMDI of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints. 